A Phase 2 interventional study of Placebo and Avatrombopag tablets in Chronic Idiopathic Thrombocytopenic Purpura and Purpura, Thrombocytopenic, Idiopathic, sponsored by Eisai Inc.. Completed at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-03-07.
Sponsored by Eisai Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. avatrombopag · Purpura, Thrombocytopenic, Idiopathic.
Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 5th largest by enrollment, is one of 2 that started in 2007, is one of 4 in phase 2, and was the 1st registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 2 countries. Recruiting first, the newest first:
Al-Mustansiriyah University · Sites in Iraq
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 6–18
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China
Ages 18+
Ostfold Hospital Trust
Ages 18+
By country, each count listing its studies:
avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 7 · Phase 4 2
First in 2007; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 53 across the 16 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 16 have an industry lead sponsor. The 5 most frequent:
This study is registered under Eisai Inc., one of the names counted as Eisai Co., Ltd.. Under that name alone:
Eisai Inc. is the lead sponsor of 368 studies on the registry; 7 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 56 (67%) have results posted.
Eisai Co., Ltd. has 8 studies filed under Purpura, Thrombocytopenic, Idiopathic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy, safety and tolerability, of AKR-501 (avatrombopag) tablets, as compared to placebo, in the treatment of participants with chronic Idiopathic Thrombocytopenic Purpura (ITP).
This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled, dose-ranging, parallel-group study. The pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/PD) relationship of avatrombopag will also be studied. Approximately 65 eligible participants will be randomized in a 3:3:3:3:1 ratio in a double-blinded fashion into one of five parallel treatment groups to receive daily doses of either avatrombopag 2.5, 5, 10 or 20 mg or placebo for 28 days, respectively. Each avatrombopag dosing group will consist of 15 participants while the placebo group will consist of 5 participants. All study participants will be evaluated weekly (Days 3, 5, 7, 14, 21 and 28) for safety, efficacy, and (Days 7, 14, 21, and 28) avatrombopag PK while receiving study treatment with a final assessment for safety and effectiveness to be done 2 weeks after the last study dose (Day 42).
At the completion of Visit Day 28±1, participants who complete 28±1 days of study dosing will be assessed for eligibility to enroll into the rollover Study 501-CL-004 (NCT00625443) based on this visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Platelet count:
Exclusion Criteria:
Use of the following drugs or treatments prior to Day 1:
Laboratory abnormalities:
History of, or current alcohol or drug abuse likely to interfere with ability to comply with protocol.
requirements or give , as determined by the Investigator.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2.5, 5, 10 or 20 mg tablets 1 tablet taken orally once daily for 28 days
Drug: Avatrombopag tablets
2.5, 5, 10, or 20 mg tablets 1 tablet taken orally once daily for 28 days
Drug: Placebo
Placebo tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
Avatrombopag tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
Also known as: AKR-501, E5501, YM477
Responder Rate (RR) to Avatrombopag on Day 28
Platelet counts were measured from the participant's blood, which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Day 28. The RR was defined as the percentage of participants with a Day 1 platelet count of less than 30,000/milliliter (mL) who reached a platelet count of greater than or equal to 50,000/mL on Day 28 of study medication, together with the percentage of participants using steroids who had a Day 1 platelet count greater than or equal to 30,000/mL but less than 50,000/mL who reached a platelet count of greater than or equal to 20,000/mL higher than their Day 1 platelet count on Day 28 of study medication. The RR was summarized by treatment group using the method of last observation carried forward (LOCF).
Time frame: Day-4 to Day 1, Baseline, Day 28
Change in Platelet Count From Baseline
Platelet counts were measured from the participant's, blood which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28. The unit of measure was "K/mm\^3", where "K = platelets x 1000 = platelets x 10\^3" and "mm\^3 = cubic milliliter= microliter".
Time frame: Day -4 to Day 1, Baseline, Day 7, Day 14, Day 21, Day 28
Responder Rate to Avatrombopag by Visit
Platelet counts were measured from the participant's blood, which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, and 21. The RR was summarized by treatment group using the method of LOCF. Day 28 was not included with this data because it was reported as a primary outcome measure.
Time frame: Day -4 to Day 1, Baseline, Day 7, Day 14, and Day 21
Percentage of Participants With Platelet Counts Greater Than or Equal to 50,000/mL by Visit
Platelet counts were measured from the participant's blood, which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28.
Time frame: Day -4 to Day 1, Baseline, Day 7, Day 14, Day 21, and Day 28
Percentage of Participants With Platelet Counts Greater Than or Equal to 100,000/mL by Visit
Platelet counts were measured from the participant's, blood which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28.
Time frame: Day -4 to Day 1, Baseline, Day 7, Day 14, Day 21, and Day 28
Percentage of Participants Whose Platelet Counts Doubled From Baseline by Visit
Platelet counts were measured from the participant's, blood which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28.
Time frame: Day -4 to Day 1, Baseline, Day 7, Day 14, Day 21, and Day 28
To Evaluate the Pharmacokinetics (PK) and the Pharmacokinetic/Pharmacodynamic (PK/PD) Relationship of Avatrombopag in Patients With ITP.
Given the sparse PK sampling in this study, PK data from outside studies, which includes healthy subjects, were included to assist in PK model development. As a result this data was not reported with these study results.
Time frame: Days 7, 14, 21 and 28
| Milestone | 2.5 mg Avatrombopag | 5.0 mg Avatrombopag | 10.0 mg Avatrombopag | 20.0 mg Avatrombopag | Placebo |
|---|---|---|---|---|---|
| Started | 15 | 15 | 14 | 15 | 5 |
| Completed | 13 | 14 | 12 | 13 | 5 |
| Not completed | 2 | 1 | 2 | 2 | 0 |
| Withdrew: Adverse event | 0 | 1 | 1 | 0 | 0 |
| Withdrew: Platelet increase;more than 500,000 mm^3 | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 |
Platelet counts were measured from the participant's blood, which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Day 28. The RR was defined as the percentage of participants with a Day 1 platelet count of less than 30,000/milliliter (mL) who reached a platelet count of greater than or equal to 50,000/mL on Day 28 of study medication, together with the percentage of participants using steroids who had a Day 1 platelet count greater than or equal to 30,000/mL but less than 50,000/mL who reached a platelet count of greater than or equal to 20,000/mL higher than their Day 1 platelet count on Day 28 of study medication. The RR was summarized by treatment group using the method of last observation carried forward (LOCF).
| Percentage of participants | 2.5 mg Avatrombopag | 5.0 mg Avatrombopag | 10.0 mg Avatrombopag | 20.0 mg Avatrombopag | Placebo |
|---|---|---|---|---|---|
| Responder Rate (RR) to Avatrombopag on Day 28 | 13.3 | 53.3 | 50.0 | 80.0 | 0 |
Platelet counts were measured from the participant's, blood which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28. The unit of measure was "K/mm\^3", where "K = platelets x 1000 = platelets x 10\^3" and "mm\^3 = cubic milliliter= microliter".
| platelets x 10^3/mm^3 | 2.5 mg Avatrombopag | 5.0 mg Avatrombopag | 10.0 mg Avatrombopag | 20.0 mg Avatrombopag | Placebo |
|---|---|---|---|---|---|
| Day 7 | 13.6 ± 22.37 | 46.7 ± 55.22 | 68.3 ± 81.23 | 168.8 ± 114.59 | 5.0 ± 9.54 |
| Day 14 | 12.5 ± 22.64 | 57.5 ± 74.72 | 103.1 ± 119.55 | 332.4 ± 278.96 | -1.4 ± 4.16 |
| Day 21 | 7.5 ± 18.38 | 47.1 ± 54.54 | 80.6 ± 129.98 | 261.3 ± 278.17 | 8.4 ± 13.72 |
| Day 28 | 7.3 ± 23.74 | 43.7 ± 50.35 | 81.0 ± 124.55 | 200.2 ± 292.36 | -1.8 ± 7.73 |
Platelet counts were measured from the participant's blood, which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, and 21. The RR was summarized by treatment group using the method of LOCF. Day 28 was not included with this data because it was reported as a primary outcome measure.
| Percentage of participants | 2.5 mg Avatrombopag | 5.0 mg Avatrombopag | 10.0 mg Avatrombopag | 20.0 mg Avatrombopag | Placebo |
|---|---|---|---|---|---|
| Day 7 | 6.7 | 66.7 | 64.3 | 93.3 | 0 |
| Day 14 | 20.0 | 60.0 | 78.6 | 93.3 | 0 |
| Day 21 | 13.3 | 60.0 | 50.0 | 86.7 | 0 |
Platelet counts were measured from the participant's blood, which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28.
| Percentage of participants | 2.5 mg Avatrombopag | 5.0 mg Avatrombopag | 10.0 mg Avatrombopag | 20.0 mg Avatrombopag | Placebo |
|---|---|---|---|---|---|
| Day 7 | 6.7 | 66.7 | 64.3 | 93.3 | 0 |
| Day 14 | 20.0 | 60.0 | 78.6 | 93.3 | 0 |
| Day 21 | 13.3 | 60.0 | 50.0 | 86.7 | 20.0 |
| Day 28 | 13.3 | 53.3 | 50.0 | 80.0 | 0 |
Platelet counts were measured from the participant's, blood which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28.
| Percentage of participants | 2.5 mg Avatrombopag | 5.0 mg Avatrombopag | 10.0 mg Avatrombopag | 20.0 mg Avatrombopag | Placebo |
|---|---|---|---|---|---|
| Day 7 | 6.7 | 20.0 | 28.6 | 80.0 | 0 |
| Day 14 | 0 | 26.7 | 42.9 | 86.7 | 0 |
| Day 21 | 0 | 20.0 | 21.4 | 73.3 | 0 |
| Day 28 | 6.7 | 33.3 | 28.6 | 53.3 | 0 |
Platelet counts were measured from the participant's, blood which was drawn at their Screening Visit B (Day -4 to Day 1, Baseline), and on study drug treatment Days 7, 14, 21, and 28.
| Percentage of participants | 2.5 mg Avatrombopag | 5.0 mg Avatrombopag | 10.0 mg Avatrombopag | 20.0 mg Avatrombopag | Placebo |
|---|---|---|---|---|---|
| Day 7 | 33.3 | 60.0 | 78.6 | 93.3 | 20.0 |
| Day 14 | 26.7 | 60.0 | 71.4 | 93.3 | 0 |
| Day 21 | 6.7 | 60.0 | 64.3 | 86.7 | 20.0 |
| Day 28 | 13.3 | 53.3 | 57.1 | 86.7 | 20.0 |
Given the sparse PK sampling in this study, PK data from outside studies, which includes healthy subjects, were included to assist in PK model development. As a result this data was not reported with these study results.
No measurements were reported for this outcome.
Collected over Adverse events (AEs) and serious adverse events (SAEs) were collected from first dose of study drug until last follow-up visit, or 30 days following discontinuation of study drug, whichever occurred later, or approximately 91 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 2.5 mg Avatrombopag | — | 2/15 (13.3%) | 12/15 (80%) |
| 5.0 mg Avatrombopag | — | 0/15 (0%) | 13/15 (86.7%) |
| 10.0 mg Avatrombopag | — | 1/14 (7.1%) | 11/14 (78.6%) |
| 20.0 mg Avatrombopag | — | 0/15 (0%) | 14/15 (93.3%) |
| Placebo | — | 0/5 (0%) | 4/5 (80%) |
| Event | 2.5 mg Avatrombopag | 5.0 mg Avatrombopag | 10.0 mg Avatrombopag | 20.0 mg Avatrombopag | Placebo |
|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/15 | 0/15 | 1/14 | 0/15 | 0/5 |
| Renal artery occlusionEye disorders | 0/15 | 0/15 | 1/14 | 0/15 | 0/5 |
| PneumoniaInfections and infestations | 0/15 | 0/15 | 1/14 | 0/15 | 0/5 |
| Transient ischaemic attackNervous system disorders | 0/15 | 0/15 | 1/14 | 0/15 | 0/5 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/15 | 0/15 | 0/14 | 0/15 | 0/5 |
| Gastric haemorrhagicGastrointestinal disorders | 1/15 | 0/15 | 0/14 | 0/15 | 0/5 |
| Event | 2.5 mg Avatrombopag | 5.0 mg Avatrombopag | 10.0 mg Avatrombopag | 20.0 mg Avatrombopag | Placebo |
|---|---|---|---|---|---|
| FatigueGeneral disorders | 2/15 | 4/15 | 4/14 | 2/15 | 1/5 |
| Platelet count increasedInvestigations | 0/15 | 0/15 | 0/14 | 4/15 | 0/5 |
| HeadacheNervous system disorders | 4/15 | 3/15 | 1/14 | 4/15 | 1/5 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 4/15 | 2/15 | 1/14 | 2/15 | 1/5 |
| EcchymosisSkin and subcutaneous tissue disorders | 0/15 | 0/15 | 3/14 | 0/15 | 0/5 |
| AnaemiaBlood and lymphatic system disorders | 0/15 | 0/15 | 0/14 | 1/15 | 1/5 |
| Auricular swellingEar and labyrinth disorders | 0/15 | 0/15 | 0/14 | 0/15 | 1/5 |
| DyspepsiaGastrointestinal disorders | 1/15 | 0/15 | 1/14 | 0/15 | 1/5 |
| HaematocheziaGastrointestinal disorders | 0/15 | 1/15 | 0/14 | 0/15 | 1/5 |
| Bowel sounds abnormalGastrointestinal disorders | 0/15 | 0/15 | 0/14 | 0/15 | 1/5 |
Randomized (Intent-to-Treat) population included all participants who were randomly assigned to treatment.
| Age, Continuous(Years) | 2.5 mg Avatrombopag | 5.0 mg Avatrombopag | 10.0 mg Avatrombopag | 20.0 mg Avatrombopag | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 52.9 ± 17.84 | 55.6 ± 18.03 | 57.5 ± 17.88 | 47.9 ± 16.54 | 39.6 ± 20.63 | 52.3 ± 17.81 |
| Sex: Female, Male(Participants) | 2.5 mg Avatrombopag | 5.0 mg Avatrombopag | 10.0 mg Avatrombopag | 20.0 mg Avatrombopag | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 9 | 9 | 8 | 11 | 3 | 40 |
| Male | 6 | 6 | 6 | 4 | 2 | 24 |
The record gives a start of Feb 2007, a primary completion of Jan 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2018, 9 years after primary completion. A results delay was requested in May 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Avatrombopag
Purpura, Thrombocytopenic, Idiopathic →